Vir Biotechnology Quarterly Balance Sheets Chart
Quarterly
|
Annual
Vir Biotechnology Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||
| cash and cash equivalents | 211,104,000 | 273,571,000 | 222,947,000 | 168,350,000 | 296,864,000 | 160,711,000 | 241,576,000 | 452,100,000 | 666,949,000 | 824,913,000 | 848,631,000 | 963,735,000 | 1,505,183,000 | 812,355,000 | 347,815,000 | 714,521,000 | 741,951,000 | 521,396,000 | 436,575,000 | 462,521,000 | 371,781,000 | 168,418,000 | 109,335,000 | 93,698,000 |
| short-term investments | 387,645,000 | 517,367,000 | 678,051,000 | 740,607,000 | 849,833,000 | 985,125,000 | 1,270,980,000 | 1,233,628,000 | 1,166,953,000 | 1,406,579,000 | 1,521,517,000 | 1,359,945,000 | 654,113,000 | 399,829,000 | 217,182,000 | 55,560,000 | 84,107,000 | 211,636,000 | 300,286,000 | 364,074,000 | 180,599,000 | 187,193,000 | 274,101,000 | 226,512,000 |
| restricted cash and cash equivalents, current | 88,218,000 | 88,151,000 | 89,385,000 | 89,598,000 | 13,946,000 | 13,335,000 | 13,268,000 | 13,193,000 | 13,163,000 | 10,957,000 | 12,681,000 | 12,955,000 | 13,147,000 | 14,402,000 | 8,594,000 | 6,112,000 | 7,004,000 | 8,601,000 | 7,993,000 | 9,363,000 | 11,024,000 | 9,101,000 | 6,181,000 | 8,822,000 |
| equity investments | 7,270,000 | 10,724,000 | 4,350,000 | 5,517,000 | 4,368,000 | 3,927,000 | 9,853,000 | 10,825,000 | 13,531,000 | 18,583,000 | 31,892,000 | 22,801,000 | 36,407,000 | 47,890,000 | 143,148,000 | 169,369,000 | ||||||||
| prepaid expenses and other current assets | 41,469,000 | 42,394,000 | 47,725,000 | 43,085,000 | 40,729,000 | 49,999,000 | 52,549,000 | 59,430,000 | 85,736,000 | 97,602,000 | 104,356,000 | 54,180,000 | 72,417,000 | 69,911,000 | 73,003,000 | 27,772,000 | 29,233,000 | 26,481,000 | 27,511,000 | 13,614,000 | 15,357,000 | 12,829,000 | 13,378,000 | 8,688,000 |
| total current assets | 735,706,000 | 932,207,000 | 1,042,458,000 | 1,047,157,000 | 1,205,740,000 | 1,213,097,000 | 1,588,226,000 | 1,769,176,000 | 1,946,332,000 | 2,358,634,000 | 2,519,077,000 | 2,413,616,000 | 2,288,267,000 | 2,567,548,000 | 1,562,821,000 | 1,066,337,000 | 862,295,000 | 993,114,000 | 772,365,000 | 849,572,000 | 578,761,000 | 377,541,000 | 402,995,000 | 337,720,000 |
| intangible assets | 7,998,000 | 8,072,000 | 8,120,000 | 19,258,000 | 18,899,000 | 22,465,000 | 22,565,000 | 25,457,000 | 25,590,000 | 32,622,000 | 32,755,000 | 32,888,000 | 33,021,000 | 33,154,000 | 33,287,000 | 33,421,000 | 33,554,000 | 33,687,000 | 33,820,000 | 33,944,000 | 35,082,000 | 35,388,000 | 35,694,000 | 35,999,000 |
| goodwill | 16,937,000 | 16,937,000 | 16,937,000 | 16,938,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 | 16,937,000 |
| property and equipment | 60,795,000 | 61,681,000 | 63,183,000 | 64,791,000 | 66,063,000 | 92,477,000 | 96,018,000 | 99,309,000 | 104,126,000 | 103,758,000 | 105,609,000 | 100,226,000 | 85,135,000 | 65,583,000 | 42,834,000 | 26,610,000 | 20,251,000 | 17,291,000 | 17,946,000 | 16,948,000 | 16,311,000 | 16,238,000 | 16,308,000 | 15,448,000 |
| operating lease right-of-use assets | 64,853,000 | 58,559,000 | 60,779,000 | 62,266,000 | 70,346,000 | 72,622,000 | ||||||||||||||||||
| restricted cash and cash equivalents, noncurrent | 6,956,000 | 6,273,000 | 6,363,000 | 6,382,000 | 6,366,000 | 6,428,000 | 6,448,000 | 7,057,000 | 6,744,000 | 6,739,000 | 6,656,000 | 7,276,000 | 8,354,000 | 9,040,000 | 7,006,000 | 6,999,000 | 7,002,000 | 6,998,000 | 6,919,000 | 1,201,000 | 1,192,000 | 1,192,000 | 7,300,000 | 2,850,000 |
| long-term investments | 286,099,000 | 218,140,000 | 190,015,000 | 271,495,000 | 279,992,000 | 359,724,000 | 105,275,000 | 39,617,000 | 52,358,000 | 49,187,000 | 23,927,000 | 34,102,000 | 97,585,000 | 103,535,000 | 201,388,000 | 50,680,000 | 6,139,000 | 24,290,000 | ||||||
| other assets | 13,188,000 | 5,858,000 | 12,057,000 | 11,556,000 | 13,292,000 | 12,495,000 | 12,409,000 | 14,720,000 | 16,853,000 | 16,554,000 | 14,570,000 | 6,209,000 | 2,816,000 | 3,001,000 | 2,775,000 | 2,343,000 | 7,890,000 | 7,096,000 | 8,827,000 | 9,895,000 | 8,778,000 | 7,672,000 | 8,547,000 | 13,688,000 |
| total assets | 1,192,532,000 | 1,307,727,000 | 1,398,813,000 | 1,498,356,000 | 1,669,555,000 | 1,793,969,000 | 1,919,060,000 | 2,044,895,000 | 2,243,874,000 | 2,665,936,000 | 2,802,088,000 | 2,695,970,000 | 2,618,994,000 | 2,887,129,000 | 1,954,268,000 | 1,210,213,000 | 1,057,581,000 | 1,135,584,000 | 918,761,000 | 943,259,000 | 672,238,000 | 477,114,000 | 512,071,000 | 422,642,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||
| accounts payable | 12,234,000 | 3,725,000 | 5,081,000 | 7,305,000 | 4,389,000 | 7,114,000 | 6,334,000 | 3,627,000 | 12,362,000 | 12,149,000 | 6,422,000 | 2,722,000 | 10,618,000 | 10,955,000 | 6,521,000 | 4,225,000 | 11,032,000 | 3,701,000 | 5,077,000 | 6,796,000 | 4,382,000 | 18,768,000 | 5,881,000 | 5,815,000 |
| accrued and other liabilities | 82,661,000 | 104,126,000 | 85,873,000 | 94,658,000 | 75,321,000 | 72,260,000 | 104,220,000 | 146,111,000 | 197,580,000 | 455,922,000 | 489,090,000 | 282,616,000 | 354,086,000 | 577,669,000 | 236,512,000 | 64,845,000 | 64,074,000 | 70,069,000 | 76,936,000 | 44,339,000 | 38,560,000 | 21,918,000 | ||
| deferred revenue, current | 10,109,000 | 11,935,000 | 12,648,000 | 15,198,000 | 16,702,000 | 14,694,000 | 64,853,000 | 15,312,000 | 6,181,000 | |||||||||||||||
| contingent consideration obligation, current | 17,500,000 | 16,060,000 | ||||||||||||||||||||||
| total current liabilities | 105,004,000 | 137,286,000 | 119,662,000 | 117,161,000 | 96,412,000 | 94,068,000 | 175,407,000 | 165,050,000 | 225,623,000 | 485,288,000 | 511,029,000 | 308,203,000 | 477,868,000 | 702,361,000 | 341,242,000 | 233,724,000 | 146,024,000 | 361,099,000 | 99,064,000 | 76,998,000 | 54,940,000 | 56,396,000 | 59,206,000 | 44,316,000 |
| operating lease liabilities, noncurrent | 93,405,000 | 88,170,000 | 90,139,000 | 93,405,000 | 95,018,000 | 109,171,000 | 111,673,000 | 114,119,000 | 117,815,000 | 121,461,000 | 123,837,000 | 126,942,000 | 130,205,000 | 132,813,000 | 133,561,000 | 68,604,000 | 68,938,000 | 66,615,000 | 66,556,000 | 12,092,000 | 12,762,000 | 13,531,000 | ||
| contingent consideration obligation, noncurrent | 33,620,000 | 23,640,000 | 24,050,000 | |||||||||||||||||||||
| other long-term liabilities | 13,031,000 | 14,812,000 | 14,577,000 | 13,893,000 | 13,855,000 | 14,238,000 | 14,258,000 | 13,134,000 | 12,094,000 | 8,235,000 | 7,862,000 | 7,166,000 | 7,596,000 | 7,746,000 | 2,540,000 | 3,823,000 | 3,853,000 | 3,815,000 | 3,847,000 | 2,982,000 | 2,967,000 | 2,942,000 | 3,568,000 | 3,030,000 |
| total liabilities | 245,060,000 | 263,908,000 | 248,428,000 | 257,629,000 | 235,885,000 | 246,613,000 | 328,824,000 | 369,810,000 | 433,666,000 | 695,135,000 | 724,125,000 | 546,115,000 | 666,982,000 | 886,115,000 | 522,419,000 | 333,939,000 | 320,256,000 | 484,633,000 | 201,909,000 | 130,904,000 | 108,459,000 | 96,781,000 | 88,129,000 | 66,827,000 |
| commitments and contingencies | ||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2025 and december 31, 2024; no shares issued and outstanding as of june 30, 2025 and december 31, 2024 | ||||||||||||||||||||||||
| common stock | 14,000 | 14,000 | 14,000 | 14,000 | 14,000 | 14,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 13,000 | 12,000 | 11,000 | 11,000 | 1,000 |
| additional paid-in capital | 1,941,386,000 | 1,926,529,000 | 1,911,872,000 | 1,894,781,000 | 1,878,013,000 | 1,852,839,000 | 1,828,862,000 | 1,798,823,000 | 1,771,536,000 | 1,737,626,000 | 1,709,835,000 | 1,682,882,000 | 1,656,024,000 | 1,625,785,000 | 1,571,535,000 | 1,541,422,000 | 1,512,928,000 | 1,488,337,000 | 1,385,301,000 | 1,374,362,000 | 1,040,988,000 | 825,833,000 | 793,051,000 | 23,869,000 |
| accumulated other comprehensive loss | -2,221,000 | -1,975,000 | -1,717,000 | -2,879,000 | -2,397,000 | -815,000 | -1,900,000 | -2,903,000 | -3,219,000 | -9,122,000 | -11,880,000 | -7,553,000 | -4,805,000 | -1,099,000 | -1,307,000 | -1,334,000 | -1,304,000 | -1,278,000 | -485,000 | -295,000 | -601,000 | |||
| accumulated deficit | -991,707,000 | -880,749,000 | -759,784,000 | -655,195,000 | -441,478,000 | -303,100,000 | -138,600,000 | -663,854,000 | -774,282,000 | -836,095,000 | -667,184,000 | -561,535,000 | -476,926,000 | -445,759,000 | -368,519,000 | -304,748,000 | ||||||||
| total stockholders’ equity | 947,472,000 | 1,043,819,000 | 1,150,385,000 | 1,240,727,000 | 1,433,670,000 | 1,547,356,000 | 1,590,236,000 | 1,675,085,000 | 1,810,208,000 | 1,970,801,000 | 2,077,963,000 | 2,149,855,000 | 1,952,012,000 | 2,001,014,000 | 1,431,849,000 | 876,274,000 | 737,325,000 | 650,951,000 | 716,852,000 | 812,355,000 | 563,779,000 | 380,333,000 | 423,942,000 | |
| total liabilities and stockholders’ equity | 1,192,532,000 | 1,307,727,000 | 1,398,813,000 | 1,498,356,000 | 1,669,555,000 | 1,793,969,000 | 1,919,060,000 | 2,044,895,000 | 2,243,874,000 | 2,665,936,000 | 2,802,088,000 | 2,695,970,000 | 2,618,994,000 | 2,887,129,000 | 1,954,268,000 | 1,210,213,000 | 1,057,581,000 | 1,135,584,000 | 918,761,000 | 943,259,000 | 672,238,000 | 477,114,000 | ||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2025 and december 31, 2024; no shares issued and outstanding as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||
| operating right-of-use assets | 59,680,000 | 71,182,000 | 74,934,000 | 81,505,000 | 82,557,000 | 84,716,000 | 86,879,000 | 88,331,000 | 87,220,000 | 57,566,000 | 58,972,000 | 60,461,000 | 61,947,000 | 14,762,000 | 15,177,000 | 16,007,000 | ||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of december 31, 2024 and 2023, respectively; no shares issued and outstanding as of december 31, 2024 and 2023 | ||||||||||||||||||||||||
| contingent consideration, noncurrent | 33,170,000 | 30,600,000 | 27,610,000 | 25,960,000 | 24,300,000 | 24,927,000 | 23,691,000 | 24,937,000 | 30,712,000 | 28,455,000 | 18,891,000 | 22,822,000 | 20,720,000 | 42,692,000 | 46,036,000 | 25,374,000 | 31,712,000 | 30,670,000 | 14,045,000 | 9,380,000 | 3,343,000 | |||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of september 30, 2024 and december 31, 2023; no shares issued and outstanding as of september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||
| accumulated other comprehensive gain | 1,127,000 | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2024 and december 31, 2023; no shares issued and outstanding as of june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||
| deferred revenue, noncurrent | 1,526,000 | 1,526,000 | 53,207,000 | 53,207,000 | 53,207,000 | 53,207,000 | 54,653,000 | 4,419,000 | 5,865,000 | 3,815,000 | 3,815,000 | 55,496,000 | 3,815,000 | 3,815,000 | 3,815,000 | 3,815,000 | 6,562,000 | 12,670,000 | 8,408,000 | |||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2024 and december 31, 2023; no shares issued and outstanding as of march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of december 31, 2023 and 2022, respectively; no shares issued and outstanding as of december 31, 2023 and 2022 | ||||||||||||||||||||||||
| (accumulated deficit) retained earnings | -237,824,000 | -121,851,000 | ||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of september 30, 2023 and december 31, 2022; no shares issued and outstanding as of september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||
| deferred revenue, current portion | 15,681,000 | 17,217,000 | 15,517,000 | 22,865,000 | 113,164,000 | 113,737,000 | 98,209,000 | 96,154,000 | 44,718,000 | 262,929,000 | 6,451,000 | 5,563,000 | 7,298,000 | 5,010,000 | 8,822,000 | |||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2023 and december 31, 2022; no shares issued and outstanding as of june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||
| retained earnings | 41,562,000 | 236,337,000 | 377,237,000 | 478,840,000 | 303,528,000 | 380,021,000 | ||||||||||||||||||
| deferred tax liability | 3,253,000 | 3,253,000 | 18,439,000 | 18,439,000 | 18,439,000 | 18,439,000 | 3,253,000 | 3,253,000 | 3,253,000 | 3,253,000 | 3,305,000 | 3,305,000 | 3,305,000 | 3,305,000 | 3,305,000 | |||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2023 and december 31, 2022; no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||
| total vir stockholder's equity | 1,970,757,000 | |||||||||||||||||||||||
| noncontrolling interest | 44,000 | |||||||||||||||||||||||
| receivable from collaboration | 7,000,000 | 1,223,161,000 | 773,079,000 | 93,003,000 | 112,500,000 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of december 31, 2022 and 2021, respectively; no shares issued and outstanding as of december 31, 2022 and 2021 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of september 30, 2022 and december 31, 2021; no shares issued and outstanding as of september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2022 and december 31, 2021; no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||
| contingent consideration, current portion | 68,500,000 | 26,200,000 | 24,400,000 | 10,600,000 | 20,300,000 | 4,700,000 | 10,700,000 | 6,726,000 | ||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2022 and december 31, 2021; no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of december 31, 2021 and 2020, respectively; no shares issued and outstanding as of december 31, 2021 and 2020 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of september 30, 2021 and december 31, 2020; no shares issued and outstanding as of september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2021 and december 31, 2020; no shares issued and outstanding as of june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||
| contract asset | 112,500,000 | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2021 and december 31, 2020; no shares issued and outstanding as of march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||
| derivative liability | 12,449,000 | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of december 31, 2020 and 2019, respectively; no shares issued and outstanding as of december 31, 2020 and 2019 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of september 30, 2020 and december 31, 2019; no shares issued and outstanding as of september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2020 and december 31, 2019; no shares issued and outstanding as of june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2020 and december 31, 2019; no shares issued and outstanding as of march 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||
| accumulated other comprehensive income | 248,000 | 81,000 | ||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||
| accrued liabilities | 26,495,000 | 22,953,000 | ||||||||||||||||||||||
| advanced proceeds from preferred stock financing | ||||||||||||||||||||||||
| contingent consideration, current | 8,200,000 | |||||||||||||||||||||||
| convertible preferred stock warrant liability | 4,425,000 | |||||||||||||||||||||||
| convertible preferred stock | 636,612,000 | |||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 and zero shares authorized as of december 31, 2019 and 2018, respectively; no shares issued and outstanding as of december 31, 2019 and 2018 | ||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 512,071,000 | |||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ deficit | ||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||
| total stockholders’ deficit | -280,797,000 | |||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ deficit | 422,642,000 |
We provide you with 20 years of balance sheets for Vir Biotechnology stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Vir Biotechnology. Explore the full financial landscape of Vir Biotechnology stock with our expertly curated balance sheets.
The information provided in this report about Vir Biotechnology stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.